Entries by Bruce Carlson

Microbiome Applications in IVD

It’s beyond theory.  The microbiome is one of many trends that align well with the IVD market.  It is explored in Kalorama Information’s study of the in vitro diagnostic market, The Worldwide Market for In Vitro Diagnostic Tests along with other trends such as automation and gene editing.   The continuous search of the etiology of […]

COVID-19 Diagnostics Blog: Abbott Antigen Test; Quidel Sales Boom; Biomarkers for COVID-19 Severity

Hundreds of Tests on The Market, U.S. Labs Mostly Use Ten

As the COVID-19 crisis surfaced in the United States, molecular diagnostic manufacturers went to work with new RT-PCR testing kits.  There have been hundreds of tests on the market receiving EUAs from the Food and Drug Administration, but a survey from the Association of Molecular Pathology demonstrated that only a few are used by laboratories.  As part of its survey: https://www.amp.org/advocacy/sars-cov-2-survey/ labs were asked their top ten testing methods.   Among them: Abbott m2000, Roche cobas were the top two vendors in most labs’ top tens.

,

Diagnostics Market to Exceed 80 Billion Dollars in 2020 as Volume of COVID-19 Testing Continues

The world market for in vitro diagnostics will reach 83.3 billion dollars in 2020, when the molecular and antibody sales of COVID-19 testing is considered.   This is according to our latest report, The Worldwide Market for In Vitro Diagnostics, 13th Edition, due out August 26th. Molecular diagnostics, for the first time in Kalorama Information’s two-decade […]

,

COVID-19 Is Positive and Negative for Digital Pathology

Our latest report finds that digital pathology market is 710 million in 2020. The COVID-19 pandemic, while disrupting healthcare in general, also provides a selling point as many pathologists are now at home and need to work digitally. Kalorama Information’s recent study Digital Pathology Markets, 2020-2025, finds a vibrant market that is pushed by the […]

Thermo and Qiagen Merger Changes Molecular Diagnostics

As Kalorama publishes its latest update in molecular diagnostics, finding a 13 billion-dollar market, a major merger is set to change things.  Here’s what to expect. The market picture for molecular diagnostics had remained stable over the years.   While there are scores of molecular diagnostic companies, and an explosion of PCR test kit companies during […]

COVID-19 Testing Increases Value of Global Molecular Diagnostics Market

As the COVID-19 crisis surfaced in the United States, molecular diagnostic manufacturers went to work with new RT-PCR testing kits. The worldwide demand for COVID tests has materialized rapidly from zero and already on course become a 1.3 billion-dollar market in the first half of 2020.  There have been hundreds of tests on the market […]

,

Could COVID-19 Influence LDT Regulation?

Lab-developed tests were controversial before the COVID-19 pandemic, and there was attempts at regulating them more in the United States.  Then came a massive infectious disease threat for which lab developed tests were essential.  The sudden onset of a disease for which there were no existing test products, so labs had to develop their own. […]

,

As COVID Testing Expands Rapidly, Recommendations and Consenus Taking Shape

The landscape of COVID-19 testing has been rapidly evolving.  New products and services are continually being introduced, and regulatory approvals have been growing and expanding to include more types of tests, samples, and sample collection methods.  With the sudden global demand and governments loosening requirements during the crisis, there has been an unprecedented flood of […]

,

COVID-19 Has Small Negative Impact on Important Companion Diagnostic Testing, Report Finds

Companion diagnostics are rising to the forefront of pharmaceutical development and treatment. Companion diagnostics increase the probability of clinical success by identifying patients with the presence of biomarkers or disease-specific therapeutic targets that can dramatically improve outcomes. The COVID-19 pandemic has gripped the world and continues to be a major area of research and development […]

Chagas: Opportunity for Testing Companies as US Army, CDC Get Involved

In Kalorama Information’s Emerging Infections Testing report (https://kaloramainformation.com/product/emerging-infectious-disease-diagnostics-markets-and-trends/) , we discussed Chagas.  Chagas disease is named after the Brazilian physician Carlos Ribeiro Justiniano Chagas, who discovered the disease in 1909. Chagas disease (Trypanosoma cruzi, known as kissing bugs) is also referred to as American trypanosomiasis. It is endemic throughout Mexico, and Central and South America, and is caused […]